Lowest Price Guaranteed
Pages
343
Last Updated
July 2026
View Count
18157
The global needle-free drug injection system market size is estimated to rise from $2,720 million currently to $5,031 million by 2035, growing at a CAGR of 5.8% during the forecast period till 2035.
 |
To learn more about this report, request a free sample copy
Needle free drug delivery devices market includes needle free injection systems and microneedle devices.
Over the years, there has been an increase in incidence rates of various chronic clinical conditions, such as diabetes, autoimmune diseases, cardiovascular diseases, and oncological diseases. Further, these are considered to be among the leading causes of death and disability across the world. In fact, the Center for Managing Chronic Disease at the University of Michigan recently reported that over 50% of the global population is suffering from some form of chronic disease. It is worth noting that these conditions can have a profound impact on the patients, since the costs and associated complications tend to grow exponentially, limiting mobility and posing an increased mortality risk. These factors have contributed to the numerous efforts made by pharmaceutical stakeholders to incorporate innovative strategies and patient centered approaches in order to address the growing burden of chronic diseases.
The current treatment options available for the chronic diseases include administration of prescribed medications through oral and parenteral routes. The choice between these routes depends on factors, such as the drug's properties, patient condition, and the desired speed and reliability of therapeutic effects. While oral administration provides convenience and patient acceptance, parenteral administration of drugs (due to several advantages, including rapid onset of action, precise dosing control and higher bioavailability) is the most prevalent method. Despite the success of conventional (parenteral) delivery approaches, which mostly rely on the intramuscular and subcutaneous routes of administration, the present scenario dictates that further improvements are required in order to deal with the associated challenges. Some of the commonly reported disadvantages of the conventional (parenteral) mode of delivery include pain during administration, risk of cross contamination, needlestick injuries, and inaccurate dosing. These factors significantly impact medication adherence and consequently affect therapeutic outcomes for patients.
In recent years, the pharmaceutical industry has witnessed technological advancements with the emergence of safer options such as safety syringe and safety needles, which incorporate technology that allows automatic retraction of the needle post-use. Furthermore, companies have also made progress on the development of latest drug delivery devices, such as needle free systems, jet injectors, pen injectors and microneedle patches. It is worth highlighting that these devices have in-built safety mechanisms (which minimize the risk of needlestick injuries) and include improvements in design, functionality and usability over conventional needles, thereby facilitating pain-free self-administration of vaccines and drugs across the dermis. This has led towards a discernible shift in patient preferences towards painless drug administration, driving the increasing acceptance and adoption of these systems. Considering this shift, from conventional to user-friendly drug delivery alternatives, the global needle free drug delivery devices market is poised to witness substantial market growth during the forecast period.
 |
 |
 |
The market research report presents an in-depth analysis of the various needle free drug delivery devices, across different segments, as defined in the table below:
| Key Report Attributes | Details | |
| Historical Trend | Since 2019 | |
| Forecast Period | Till 2035 | |
| Current Market Size | $ 2,720 Million | |
| CAGR | 5.8% | |
| Route of Administration (Needle free drug delivery devices) |
|
|
| Actuation Mechanism (Needle free drug delivery devices) |
|
|
| Product Usability (Needle free drug delivery devices) |
|
|
| Application Area (Needle free drug delivery devices) |
|
|
| Product Type (Needle free drug delivery devices) |
|
|
| Type of Load (Needle free drug delivery devices) |
|
|
| Geography (Needle free drug delivery devices) |
|
|
| Type of Microneedle (Microneedle devices) |
|
|
| Application Area (Microneedle devices) |
|
|
| Type of Material Used (Microneedle devices) |
|
|
| Type of Intervention (Microneedle devices) |
|
|
| Geography (Microneedle devices) |
|
|
| Key Companies Profiled |
|
|
| PowerPoint Presentation (Complimentary) |
Available | |
| Customization Scope | 15% Free Customization | |
| Excel Data Packs (Complimentary) |
|
|
 |
 |
 |
One of the key objectives of this needle free drug delivery device market report was to estimate the current market size, opportunity and the future growth potential over the forecast period. Based on multiple parameters, likely adoption trends and through primary validations, we have provided an informed estimate on the market evolution during the forecast period, till 2035. The needle free drug delivery devices market analysis features the likely distribution of the current and forecasted opportunity within this market across two main product categories, namely needle-free injection systems and microneedle devices.
The opportunity within the needle-free injection systems are categorized across as route of administration (subcutaneous, intramuscular and intradermal), actuation mechanism (spring-powered devices, compressed-gas devices and other devices), product usability (reusable devices and disposable devices), application area (insulin delivery, pain management, dermatology and vaccination), product type (fillable devices and prefilled devices), type of load (liquid-based devices, powder-based devices and projectile / depot-based devices) and geography (North America, Europe, Asia-Pacific, Middle East and North Africa, and Latin America).
The opportunity within the microneedle devices is categorized across type of microneedle (solid microneedles, hollow microneedles and dissolving microneedles), type of material used (polymer microneedle, silicon microneedle, metal microneedle and ceramic microneedle), application area (insulin delivery, pain management, vaccination and oncology), type of intervention (vaccines, therapeutic agents and other interventions) and geography (North America, Europe, Asia-Pacific, Middle East and North Africa, and Latin America).
In order to account for future uncertainties and to add robustness to our model, we have provided three needle free drug delivery devices market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.
The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders in the needle free drug delivery devices market. In addition, the research report features detailed transcripts of interviews held with the following industry stakeholders:
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.
Product Category: Needle-free Injection System Market
Based on the route of administration, the global needle-free injection system market is categorized into subcutaneous, intramuscular and intradermal routes. Subcutaneous route segment occupies the highest share (55%) and is expected to witness substantial growth in the coming years. This can be primarily attributed to the fact that it is widely used to administer different type of drugs including, insulin, morphine, diacetylmorphine and goserelin, owing to its high bioavailability and rapid onset of action. Further, it is highly effective in administering vaccines, growth hormones, and insulin, which require continuous delivery at a low dose.
This section highlights the distribution of global needle-free injection system market into spring-powered devices, compressed-gas devices and other devices, based on the type of actuation mechanism. The spring-powered segment occupies the highest share within the overall market in 2024, and this trend is expected to remain same during the forecast period. This can be attributed to the fact that such systems are suitable for subcutaneous, intramuscular as well as transdermal administration.
This section segments the global needle-free injection system market into reusable devices and disposable devices on the basis of product usability. With the potential of being reused for up to 5,000 injections or approximately three years, reusable needle free injections produce minimal waste, making it eco-friendly and cost efficient. Therefore, reusable injections market segment is anticipated to occupy the largest market share in the overall needle free drug delivery devices market.
Based on the product type, the global needle-free injection system market is segmented across prefilled devices and fillable devices. Currently, the fillable needle free injection segment holds a greater market share in the needle-free injection system market. This can be attributed to its ability to customize dosages by allowing on-demand filling of the injector device with the desired medication, thereby, providing flexibility in drug administration.
This segment distributes the global needle-free injection system market across liquid-based, powder-based and projectile / depot-based needle free injection systems. Presently, liquid-based needle free injectors market segment occupies the largest market share and is expected to witness substantial growth in the coming years. This is followed by the powder-based needle free injectors occupying 24% of the overall market share.
Based on the application area, the global needle-free injection system market is segmented across insulin delivery, pain management, vaccination and dermatology. Presently, insulin delivery occupies the largest share, followed by pain management. This trend is unlikely to change in the near future.
Based on key geographical regions, the needle-free injection systems market is segmented across various geographies, including North America, Europe, Asia-Pacific, Middle East and North Africa, and Latin America. According to our projections, North America is likely to capture the majority (38%) of the overall market. This can be attributed to the growing demand for safer drug delivery alternatives in this region, this trend is unlikely to change in the future.
Product Category: Microneedle Device Market
Based on the type of microneedle, the global microneedle device market is categorised into solid, hollow, dissolving and coated microneedle. Presently, hollow microneedles occupy the largest market share and is expected to witness substantial growth in the coming years. This is followed by solid microneedles occupying 30% of the overall market share.
Based on the type of material used, the global microneedle device market is categorised into polymer, silicon, metal and ceramic microneedle. Presently, polymer microneedles hold a greater market share (33%) in the microneedle devices market and this trend is likely to remain the same in the foreseen future. This can be attributed to the flexibility in design and customization offered (can be molded into various shapes and sizes easily) by polymer microneedles. In addition, many polymers that are used in microneedle technology are biocompatible and can be engineered to enhance the interaction with the skin or other tissues, thereby making them suitable for a variety of drug delivery applications.
This segment highlights the distribution of global microneedle device market across vaccines, therapeutic agents and other interventions. Presently, microneedle devices designed to deliver vaccines occupy the largest market share. This can be attributed to the fact that microneedle vaccines are able to produce an immune response similar or even higher than two shots given using the conventional administration method.
Based on the application area, the global microneedle device market is categorised into insulin delivery, pain management, infectious diseases and oncology. Presently, insulin delivery occupies the largest market share. This is followed by the market share for vaccination and pain management.
Microneedle device market is segmented across various geographies, including North America, Europe, Asia-Pacific, Middle East and North Africa, and Latin America. According to our projections, North America is likely to capture the majority of the overall market share, and this trend is unlikely to change in the future. Further, the market in Europe is expected to grow at a relatively higher CAGR (7.2%), during the forecast period, till 2035.
The “Needle Free Drug Delivery Devices Market (2nd Edition): Industry Trends and Forecasted Estimates, till 2035” market report features an extensive study of the current market landscape, market size and future opportunities for the needle free drug delivery companies, during the forecast period. Further, the market report highlights the efforts of several stakeholders engaged in this rapidly emerging industry. Key takeaways of the market report are briefly discussed below.
The needle free injection system market features nearly 50 large, mid-sized and small companies that are engaged in providing needle free injection systems / jet injectors. Currently, 91% of needle free injection systems are designed to administer liquid formulations. This can be attributed to the fact that liquid formulations increase the surface area of the drug, thereby enhancing its solubility and bioavailability. This allows for improved drug absorption and subsequent therapeutic effects. In addition, liquid needle jet injectors were one of the first variants to be developed. Notable examples of companies offering such devices include (in alphabetic order) Activa Brand Products, Aijex Pharma International, Akra Dermojet and American Medical Systems.
Furthermore, 32% of the needle free injection systems deliver drugs through intradermal route. It is interesting to highlight that, Centre for Disease Control and Prevention (CDC) claims that intradermal route of administration for vaccines can reduce the dose amount to be delivered by as much as 80 percent in some cases, thereby making it economical for both patients and healthcare facilities.
The market landscape features the presence of over 55 large, mid-sized and small companies. Over 65% of the companies were established post-2010, demonstrating the rising interest of industry stakeholders in this domain. Examples of companies established post-2010 (in alphabetical order) include AdminMed, Alma Therapeutics, Anodyne Nanotech and Clearside Biomedical. Further, it is worth highlighting that 47% of the microneedle device providers are based in North America. Within Europe, the UK emerged as the hub of microneedle device companies. Moreover, 18% of the players located in Europe were based in Germany and Ireland, each
The needle free drug delivery devices market is primarily driven by the ongoing technological advancements aimed at enhancing product and service efficiency. This is particularly advantageous for patients requiring frequent injections, as it facilitates self-administration of accurate dosage of drugs. In addition, various other factors have contributed to the increase in demand for safer alternatives, such as minimal side effects and reduced needle-stick injuries. Moreover, factors such as population growth, rise in incidence of chronic diseases and shifts in consumer preferences to safer alternatives, including jet injectors and transdermal patches have contributed to the increasing demand.
The global needle free injection system market is estimated to be worth $606 million in 2024. Driven by the fact that these drug delivery technologies have the capability to overcome multiple disadvantages associated with conventional two-piece syringe systems and deliver a wide spectrum of therapeutic molecules (without compromising the treatment regimen in anyway), the market is anticipated to grow at a steady pace during the forecast period. Further, they have the potential to replace the traditional methods of drug injection and can be expected to have good market penetration in the foreseen future. In addition, the global microneedle devices market is estimated to be currently worth $2,114 million and is expected to reach $4,101 million by 2035. The increase can be attributed to fact that these devices ease the self-administration process. Thereby, reducing hospitalization expenses, resulting in cost saving for both patients and healthcare system.
Majority of the microneedle device providers are headquartered in North America, followed by companies based in Europe. Currently, North America and Europe capture over 65% of the market share of the overall microneedle device market.
In recent years, demand for microneedle patches and systems have increased in North America, owing to the fact that administration of drugs using the microneedle device allows the drug molecules to enter directly into the epidermis. This allows more drug molecules to enter the skin, accelerating patient compliance and improved permeability and efficacy. However, in the coming years, Europe is likely to grow at a much faster rate as compared to other geographies.
Examples of key players involved in the needle free drug delivery devices industry (which have also been captured in this market report, arranged in alphabetical order) include 3M, Antares Pharma, D’Antonio Consultants International, Debiotech, HNS International, INCYTO, Injex, INOVIO Pharmaceuticals, Medical International Technology, Micropoint Technologies, Mika Medical, NanoPass Technologies, Nemaura Pharma, Pharmajet, QS Medical Technology (Quinovare), Theraject, Zogenix. This market report includes an easily searchable excel database for all the companies providing needle free drug delivery devices, worldwide.
The market report presents an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this industry, across different geographies. Amongst other elements, the market research report includes:
 |
 |
 |
Several recent developments have taken place in needle free drug delivery devices industry. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that we have outlined in our analysis.